HCM
HUTCHMED (China) Limited
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+54/100
Last price
14.60
▲ 0.29 (2.03%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
14.98
Prev close
14.31
Day high
14.75
Day low
14.54
Volume
68.47K
Market cap
$2.54B
P/E (TTM)
146.00
52W range
9.77 – 16.40
Day trading desk
Gap from prior close
+4.68%
Prior close 14.31
VWAP
14.64
-0.30% from price
Relative volume
0.98×
Normal
Session range
4.61%
14.32 – 14.98
Position in range
42%
Mid range
ATR (14D)
0.44
2.98% of price
Prior day high
14.34
PDH
Prior day low
13.90
PDL
Bid / ask spread
—
Quote not published
Session volume
66.29K
Avg 67.43K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+3.18%
+1.2%
1M
+3.62%
+2.5%
3M
+31.29%
+26.8%
6M
-5.13%
-23.3%
YTD
+9.53%
-4.7%
1Y
-9.26%
-25.7%
3Y
-13.81%
-96.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on HCM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
24.33K
Total on file
Fundamentals
Market cap$2.54B
Enterprise value$1.27B
Revenue (TTM)$549.12M
Gross profit$73.10M
EBITDA$-20.52M
Net income$17.88M
EPS (TTM)$0.10
Free cash flow$-18.88M
Total cash$1.38B
Total debt$94.51M
Book value / share$7.26
Shares outstanding173.81M
Float105.61M
Short % of float0.22%
Dividend yield0.00%
Beta (5Y)0.36
Valuation & profitability ratios
Trailing P/E146.00
Forward P/E56.32
PEG ratio—
Price / sales—
Price / book2.01
EV / revenue2.31
EV / EBITDA-61.90
Gross margin13.31%
Operating margin0.31%
Profit margin3.26%
Return on equity1.46%
Return on assets-1.24%
Debt / equity7.41
Current ratio5.64
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $548.51M | $630.20M | $838.00M | $426.41M | -13.0% |
| Operating revenue | $548.51M | $630.20M | $838.00M | $426.41M | -13.0% |
| Cost of revenue | $336.35M | $348.88M | $384.45M | $311.10M | -3.6% |
| Gross profit | $212.16M | $281.32M | $453.55M | $115.31M | -24.6% |
| Research & development | $148.29M | $212.11M | $302.00M | $386.89M | -30.1% |
| Selling, general & admin | $103.03M | $112.91M | $133.18M | $136.11M | -8.8% |
| Total operating expense | $247.86M | $321.93M | $432.04M | $521.57M | -23.0% |
| Operating income | -$35.70M | -$40.61M | $21.51M | -$406.26M | +12.1% |
| Net interest income | $47.01M | $37.21M | $35.39M | $8.95M | +26.3% |
| Pre-tax income | $498.69M | -$1.11M | $58.31M | -$410.42M | +45,148.9% |
| Tax provision | $63.61M | $7.19M | $4.51M | -$283.00K | +784.5% |
| Net income | $456.91M | $37.73M | $100.78M | -$360.83M | +1,111.0% |
| Net income to common | $456.91M | $37.73M | $100.78M | -$360.83M | +1,111.0% |
| Basic EPS | 2.65 | 0.20 | 0.60 | -2.15 | +1,225.0% |
| Diluted EPS | 2.65 | 0.20 | 0.60 | -2.15 | +1,225.0% |
| EBIT | $501.56M | $1.76M | $59.07M | -$409.77M | +28,316.8% |
| EBITDA | $514.86M | $14.11M | $67.27M | -$401.11M | +3,550.0% |
| Basic shares | 171.66M | 171.07M | 169.93M | 169.43M | +0.3% |
| Diluted shares | 174.58M | 174.57M | 173.84M | 169.43M | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $71.33M | $153.96M | $283.59M | $313.28M | — | -53.7% |
| Cash & short-term investments | $1.37B | $836.11M | $886.34M | $631.00M | — | +63.5% |
| Accounts receivable | $126.75M | $155.54M | $116.89M | $97.99M | — | -18.5% |
| Inventory | $41.13M | $50.40M | $50.26M | $56.69M | — | -18.4% |
| Total current assets | $1.57B | $1.07B | $1.10B | $839.89M | — | +47.0% |
| Property, plant & equipment | $97.65M | $97.00M | $104.39M | $84.67M | — | +0.7% |
| Goodwill & intangibles | $3.11M | $2.99M | — | — | $3.54M | +4.1% |
| Total assets | $1.75B | $1.27B | $1.28B | $1.03B | — | +37.6% |
| Total current liabilities | $315.77M | $376.56M | $403.03M | $353.90M | — | -16.1% |
| Current debt | $24.97M | $23.37M | $31.16M | $0 | — | +6.8% |
| Long-term debt | $68.19M | $59.43M | $48.19M | $18.10M | — | +14.7% |
| Total debt | $97.89M | $89.82M | $86.13M | $27.01M | — | +9.0% |
| Total liabilities | $501.83M | $502.34M | $536.39M | $392.57M | — | -0.1% |
| Retained earnings | -$378.64M | -$833.17M | -$870.87M | -$971.48M | — | +54.6% |
| Shareholder equity | $1.24B | $759.93M | $730.54M | $610.37M | — | +62.9% |
| Working capital | $1.25B | $689.99M | $693.81M | $485.99M | — | +81.4% |
| Net tangible assets | $1.23B | $756.94M | $730.54M | $610.37M | — | +63.1% |
| Shares issued | 872.33M | 871.60M | 871.26M | 864.78M | — | +0.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $457.73M | $38.17M | $101.09M | -$360.39M | +1,099.2% |
| Depreciation & amortisation | $13.31M | $12.34M | $8.21M | $8.66M | +7.8% |
| Stock-based compensation | $15.29M | $21.61M | $36.60M | $30.59M | -29.2% |
| Change in working capital | -$60.86M | -$62.17M | $71.15M | $58.70M | +2.1% |
| Operating cash flow | -$64.66M | $497.00K | $219.26M | -$268.60M | -13,109.5% |
| Capital expenditure | -$24.15M | -$17.93M | -$32.61M | -$36.66M | -34.7% |
| Investing cash flow | -$29.41M | -$96.06M | -$291.14M | $296.59M | +69.4% |
| Share buybacks | $0 | -$36.06M | -$9.07M | -$48.08M | +100.0% |
| Financing cash flow | $7.84M | -$30.67M | $48.66M | -$82.76M | +125.6% |
| Free cash flow | -$88.81M | -$17.44M | $186.65M | -$305.26M | -409.3% |
| End cash position | $71.33M | $153.96M | $283.59M | $313.28M | -53.7% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $71.33M | — | — |
| Cash & short-term investments | $1.37B | $1.36B | +0.2% |
| Accounts receivable | $126.75M | $146.97M | -13.8% |
| Inventory | $41.13M | — | — |
| Total current assets | $1.57B | $1.59B | -1.6% |
| Property, plant & equipment | $97.65M | $94.57M | +3.3% |
| Goodwill & intangibles | $3.11M | — | — |
| Total assets | $1.75B | $1.78B | -1.3% |
| Total current liabilities | $315.77M | $342.41M | -7.8% |
| Current debt | $24.97M | — | — |
| Long-term debt | $68.19M | $93.44M | -27.0% |
| Total debt | $97.89M | $93.44M | +4.8% |
| Total liabilities | $501.83M | — | — |
| Retained earnings | -$378.64M | — | — |
| Shareholder equity | $1.24B | $1.23B | +0.7% |
| Working capital | $1.25B | $1.25B | +0.1% |
| Net tangible assets | $1.23B | $1.23B | +0.5% |
| Shares issued | 872.33M | 872.11M | +0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
0.50
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
10.00
-31.5% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+18.7%
Puts bid over calls
Call volume
2
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
10.00
0 contracts
Heaviest put OI
12.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | 0.22 | 6 | $626.61M | +14.2% |
| Next year | 0.26 | 6 | $698.80M | +11.5% |
Analyst targets & ownership
Mean target$22.01
High target$40.40
Low target$13.60
Implied upside50.72%
Analyst count14
ConsensusSTRONG BUY
Strong buy / Buy2 / 9
Hold2
Sell / Strong sell0 / 0
Held by insiders0.01%
Held by institutions2.60%
Institutions holding69
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.28
+2.24% from price
SMA 20
13.96
+4.56% from price
SMA 50
12.94
+12.81% from price
SMA 100
12.04
+21.26% from price
SMA 200
13.22
+10.40% from price
EMA 12
14.21
+2.73% from price
EMA 26
13.77
+6.04% from price
EMA 50
13.20
+10.61% from price
RSI (14)
61.5
Neutral
MACD (12,26,9)
0.44
Hist -0.01
ATR (14)
0.44
2.98% of price
Realised vol 30D
58.8%
Annualised
Bollinger upper
14.92
20, 2σ
Bollinger lower
13.01
20, 2σ
50 / 200 cross
Death
12.94 vs 13.22
Trend bias
Above 200
+10.40%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.82
Less volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
58.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-39.0%
Peak to trough
Max drawdown 5Y
-78.5%
Peak to trough
ATR 14
0.44
2.98% of price
Beta (reported)
0.36
5Y monthly, from filing
Short interest
Shares short
230.03K
Prior 169.62K
Change vs prior
+35.6%
Shorts adding
% of float
0.22%
Normal
% of shares out
0.13%
Against total outstanding
Days to cover
2.1
Liquid
Float
105.61M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Jul 7, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Mar 10, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Sep 22, 25 | Morgan Stanley | DOWNGRADE | Equal-Weight | Underweight |
| Jul 22, 25 | B of A Securities | MAINTAINED | Buy | Buy |
| Aug 1, 24 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Nov 24, 23 | Deutsche Bank | UPGRADE | Hold | Buy |
| Nov 10, 23 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Sep 5, 23 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 24, 23 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Aug 9, 22 | Goldman Sachs | MAINTAINED | — | Neutral |
| Aug 2, 22 | Goldman Sachs | MAINTAINED | — | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-29
Corporate Changes & Voting Matters
6-K · 2026-09-24
Corporate Changes & Voting Matters
6-K · 2026-09-03
Corporate Changes & Voting Matters
6-K · 2026-08-31
Corporate Changes & Voting Matters
6-K · 2026-08-28
Corporate Changes & Voting Matters
6-K · 2026-08-18
Corporate Changes & Voting Matters
6-K · 2026-08-17
Corporate Changes & Voting Matters
6-K · 2026-07-30
Headlines
NIOX Group And 2 Other British Healthcare Stocks
Simply Wall St. · 5d ago
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
GlobeNewswire · 8d ago
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
GlobeNewswire · 9d ago
GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity
Insider Monkey · 12d ago
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
GlobeNewswire · 13d ago
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
MarketBeat · 34d ago
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
Proactive · 34d ago
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
Proactive · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.